| Patent Number |
Title Of Patent |
Date Issued |
| 7101907 |
Topical administration of statins for treatment of bone disorders |
September 5, 2006 |
| The topical administration of statins for the treatment of bone disorders is disclosed. |
| 6642216 |
Isoprenoid pathway inhibitors for stimulating bone growth |
November 4, 2003 |
| Compounds of the formula ##STR1##wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula ##STR2## or a stereoisomer thereof, wherein R.sup.1 is substituted or unsubstituted alkyl |
| 6395740 |
Calcitonin mimetics |
May 28, 2002 |
| Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre |
| 6391917 |
Dialkyl ureas as calcitonin mimetics |
May 21, 2002 |
| Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec |
| 6376476 |
Isoprenoid pathway inhibitors for stimulating bone growth |
April 23, 2002 |
| Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-pl |
| 6255351 |
Dialkyl ureas as calcitonin mimetics |
July 3, 2001 |
| Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec |
| 6221913 |
Dialkyl ureas as calcitonin mimetics |
April 24, 2001 |
| Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec |
| 6124299 |
Calcitonin mimetics |
September 26, 2000 |
| Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre |
| 6080779 |
Compositions and methods for stimulating bone growth |
June 27, 2000 |
| Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may opti |
| 6022887 |
Compositions and methods for stimulating bone growth |
February 8, 2000 |
| Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optio |
| 5698521 |
Native calcitonin mimetics |
December 16, 1997 |
| The invention provides isolated, biologically active native calcitonin mimetics and related methods. These small 16 and 17 amino acid proteins mimic the interaction of calcitonin on its receptor, and also exhibit bone resorptive inhibiting activity. |
| 5677334 |
Method for inhibiting the stimulation of a glucagon-induced response pathway in a warm-blooded a |
October 14, 1997 |
| Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response |
| 5508304 |
Glucagon antagonists and methods relating thereto |
April 16, 1996 |
| Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response |
